Non-steroidal anti-inflammatory drug use and inflammatory markers associated with gallbladder dysplasia: A case-control analysis within a series of patients undergoing cholecystectomy.
chemokines
cytokines
dysplasia
gallbladder cancer
inflammation
non‐steroidal anti‐inflammatory drugs
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
revised:
02
10
2024
received:
28
05
2024
accepted:
04
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
aheadofprint
Résumé
Inflammation has been associated with the development of gallbladder cancer (GBC). However, little is known about the associations of both, inflammation and the use of non-steroidal anti-inflammatory drugs (NSAIDs), with preneoplastic lesions. We analyzed the association of NSAIDs and gallbladder dysplasia in 82 patients with dysplasia and 1843 patients with gallstones among symptomatic patients from a high-risk population. We also analyzed associations for 33 circulating immune-related proteins in a subsample of all 68 dysplasia cases diagnosed at the time of sample selection and 136 gallstone controls. We calculated age- and sex-adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs). Biliary colic was reported among most cases (97.6%) and controls (83.9%). NSAID use was inversely associated with gallbladder dysplasia (OR: 0.48, 95%CI: 0.26-0.83). Comparing the highest versus lowest category of each immune-related protein, eight proteins were inversely associated with dysplasia with sex- and age-adjusted ORs ranging from 0.30 (95%CI: 0.12-0.77) for IL-33 to 0.76 (95%CI: 0.59-0.99) for MIP-1B. Of those, GRO remained associated with dysplasia (OR: 0.64, 95%CI: 0.45-0.91) and BCA-1 was borderline associated (OR: 0.74, 95%CI: 0.54-1.01) after adjusting the logistic regression model for sex, age, and NSAIDs. In conclusion, NSAID users were less likely to have gallbladder dysplasia, suggesting that NSAIDs might be beneficial for symptomatic gallstones patients. The inverse association between immune-related markers and dysplasia requires additional research, ideally in prospective studies with asymptomatic participants, to understand the role of the inflammatory response in the natural history of GBC and to address the biological effect of NSAIDs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias
ID : 15130011
Organisme : NIH HHS
Pays : United States
Organisme : US National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1212066
Informations de copyright
© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
Hundal R, Shaffer E. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99‐109.
Roa JC, García P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022;8(1):69.
Miranda‐Filho A, Piñeros M, Ferreccio C, et al. Gallbladder and extrahepatic bile duct cancers in the Americas: incidence and mortality patterns and trends. Int J Cancer. 2020;147(4):978‐989.
Espinoza JA, Bizama C, García P, et al. The inflammatory inception of gallbladder cancer. Biochimica et Biophysica Acta. 2016;1865(2):245‐254.
Carotti S, Guarino MPL, Cicala M, et al. Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. Neurogastroenterol Motility. 2010;22(8):866.
Roa I, De Aretxabala X, Araya JC, Roa J. Preneoplastic lesions in gallbladder cancer. J Surg Oncol. 2006;93:615‐623.
Kanoh K, Shimura T, Tsutsumi S, et al. Significance of contracted cholecystitis lesions as high risk for gallbladder carcinogenesis. Cancer Lett. 2001;169(1):7‐14.
Rosa L, Lobos‐González L, Muñoz‐Durango N, et al. Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia. Mol Oncol. 2020;14(11):2834‐2852.
Liu Z, Kemp TJ, Gao YT, et al. Association of circulating inflammation proteins and gallstone disease. J Gastroenterol Hepatol. 2018;33(11):1920‐1924.
Koshiol J, Castro F, Kemp TJ, et al. Association of inflammatory and other immune markers with gallbladder cancer: results from two independent case‐control studies. Cytokine. 2016;83:217‐225.
Koshiol J, Gao YT, Corbel A, et al. Circulating inflammatory proteins and gallbladder cancer: potential for risk stratification to improve prioritization for cholecystectomy in high‐risk regions. Cancer Epidemiol. 2018;54:25‐30.
Van Erpecum KJ, Wang DQH, Moschetta A, et al. Gallbladder histopathology during murine gallstone formation: relation to motility and concentrating function. J Lipid Res. 2006;47(1):32‐41.
Rege RV, Prystowsky JB. Inflammation and a thickened mucus layer in mice with cholesterol gallstones. J Surg Res. 1998;74(1):81‐85.
Koshiol J, Wozniak A, Cook P, et al. Salmonella enterica serovar Typhi and gallbladder cancer: a case–control study and meta‐analysis. Cancer Med. 2016;5(11):3310‐3335.
Pérez‐Moreno P, Riquelme I, García P, Brebi P, Roa JC. Environmental and lifestyle risk factors in the carcinogenesis of gallbladder cancer. J Pers Med. 2022;12(2):234.
Liu E, Sakoda LC, Gao YT, et al. Aspirin use and risk of biliary tract cancer: a population‐based study in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1315‐1318.
Prasai K, Tella SH, Yadav S, et al. Aspirin and statin use and the risk of gallbladder cancer. Cancers. 2021;13(5):1186.
Marcano‐Bonilla L, Schleck CD, Harmsen WS, et al. Aspirin, statins, non‐aspirin NSAIDs, metformin, and the risk of biliary cancer: a Swedish population‐based cohort study. Cancer Epidemiol Biomarkers Prev. 2022;31(4):804‐810.
Low EE, Demb J, Liu L, et al. Risk factors for early‐onset colorectal cancer. Gastroenterology. 2020;159(2):492‐501.
Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta‐analysis through 2019. Ann Oncol. 2020;31(5):558‐568.
Koshiol J, Bellolio E, Vivallo C, et al. Distribution of dysplasia and cancer in the gallbladder: an analysis from a high cancer‐risk population. Hum Pathol. 2018;82:87‐94.
Kim S. Ppcor: an R package for a fast calculation to semi‐partial correlation coefficients. Commun Stat Appl Methods. 2015;22(6):665‐674.
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2022.
Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol. 2016;34(35):4270‐4276.
Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2(1):16024.
Wang X, Chan AT, Slattery ML, et al. Influence of smoking, body mass index, and other factors on the preventive effect of nonsteroidal anti‐inflammatory drugs on colorectal cancer risk. Cancer Res. 2018;78(16):4790‐4799.
Koshiol J, Van De Wyngard V, McGee EE, et al. The Chile biliary longitudinal study: a gallstone cohort. Am J Epidemiol. 2021;190(2):196‐206.
Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008;68(1):323‐328.
Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891‐899.
Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one‐year results of the APACC trial. Gastroenterology. 2003;125(2):328‐336.
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long‐term use of aspirin and nonsteroidal anti‐inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914‐923.
Jackson SS, Van De Wyngard V, Pfeiffer RM, et al. Inflammatory profiles in Chilean Mapuche and non‐Mapuche women with gallstones at risk of developing gallbladder cancer. Sci Rep. 2021;11(1):3686.
Maker AV, Katabi N, Qin LX, et al. Cyst fluid interleukin‐1β (IL1β) levels predict the risk of carcinoma in Intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2011;17(6):1502‐1508.
Pu N, Chen Q, Zhang J, et al. Circulating cytokines allow for identification of malignant intraductal papillary mucinous neoplasms of the pancreas. Cancer Med. 2023;12(4):3919‐3930.
DelGiorno KE, Hall JC, Takeuchi KK, et al. Identification and manipulation of biliary metaplasia in pancreatic tumors. Gastroenterology. 2014;146(1):233‐244.
DelGiorno KE, Chung CY, Vavinskaya V, et al. Tuft cells inhibit pancreatic tumorigenesis in mice by producing prostaglandin D2. Gastroenterology. 2020;159(5):1866‐1881.
O'Leary CE, Sbierski‐Kind J, Kotas ME, et al. Bile acid–sensitive tuft cells regulate biliary neutrophil influx. Sci Immunol. 2022;7(69):1201.